Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Inhibikase Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 9 | 14 | +5 |
| Shares | 162.6K | 3.79M | +3.63M (+2,233.5%) |
| Value | $975.0K | $10.6M | +$9.65M (+989.7%) |
New holders (9)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ACT Capital Management, LLC | 875,000 | $2.45M | 1.26% |
| Kepos Capital LP | 700,000 | $1.96M | 0.15% |
| Vanguard Group Inc | 470,615 | $1.32M | 0.00% |
| Sabby Management, LLC | 421,200 | $1.18M | 0.26% |
| Murchinson Ltd. | 320,947 | $899.0K | 0.33% |
| Antara Capital LP | 250,000 | $700.0K | 0.13% |
| Altium Capital Management LP | 109,749 | $307.0K | 0.07% |
| Warberg Asset Management LLC | 90,000 | $252.0K | 0.08% |
| Rockefeller Capital Management L.P. | 1,500 | $4.00K | 0.00% |
Sold out (4)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Citadel Advisors LLC | 17,857 | $107.0K |
| Millennium Management LLC | 11,224 | $67.0K |
| Royal Bank of Canada | 2,000 | $12.0K |
| Tower Research Capital LLC (TRC) | 543 | $3.00K |